Diabetes mellitus can cause significant tissue damage as manifested by nephropathy, neuropathy, and, in the eye, diabetic retinopathy. Vision loss in patients with diabetes is often associated with diabetic macular edema (DME). Because 3 different modalities of therapy, including focal laser photocoagulation, intravitreal anti–vascular endothelial growth factor (VEGF) agents, and corticosteroids, have been approved by regulatory authorities worldwide, physicians and patients are in a new era with diverse options to prevent moderate and severe vision loss from DME.1-5
Apte RS. What Is Chronic or Persistent Diabetic Macular Edema and How Should It Be Treated? JAMA Ophthalmol. 2016;134(3):285–286. doi:10.1001/jamaophthalmol.2015.5469
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: